Medicina e società
Figli di un dio minore
ABOUT THE IMMUNIZATION POLICY IN PUGLIA: MORE FOR THOSE WHO ARE NOT IN NEED
ROSARIO CAVALLO
Pediatra di famiglia, Salice Salentino (Lecce)
Gennaio 2005 - pagg. 31 -35
Abstract
The Puglia Region has recently established the free provision of pertussis, measles-mumps-rubella,
Haemophilus, pneumococcal and meningococcal vaccines. The decision does not
make any difference between vaccines which respond to well established public health needs
(pertussis, measles and rubella) and others for which the cost-benefit profile is questionable.
No guidelines were issued and responsibility for decisions is left to the family paediatricians.
This policy will significantly increase the costs for the health system without addressing the problem
of improving the immunization coverage of children who, mainly due to social disadvantage,
are currently not immunized for pertussis, measles and rubella.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Delibera Regionale del 23-2-2004, prot. 6820
2. Grandori L, D’Andrea N. Un calendario vaccinale nuovo e diverso? Quaderni acp 2003; Vol X n°3:6-7.
3. OMS. Pneumococcal vaccines. Weekly Epidemiological Record 2003;78(14):110-19.
4. Tite L. Drug company pushes for all children under 2 to be vaccinated against pneumonia. BMJ 2003;327:1249.
5. Melegaro A, Edmunds WJ. Cost effectiveness analysis of PNC conjugate vaccination in England and Wales. Vaccine 2004;22:4203-14.
6. CDC. Preventing pneumococcal disease among infants and young children. MMWR 2000;49:RR-9.
7. Whitney CG. Decline in invasive pneumococcal disease after the introduction of portein- polysaccaride conjugate vaccine. N Engl J Med 2003;348:1737-46.
8. Pneumococco: perché vaccinare mio figlio? Pacini editore, pag. 8-9.
9. Tarallo L and the Italian Pneumonet Group (Società Italiana Pediatria and Associazione Italiana Studio Antimicrobici e Resistenze). Active surveillance of S. pneumoniae bacteremia in Italian children. Poster al Convegno Nazionale, Roma, 8 Sett. 2003.
10. Castiglia P, Gallisai D, Sotgiu G. Epidemiology of invasive pneumococcal infections in Sardinian children; Poster of ISPPD-4 Helsinki 2004 (4° simposio internazionale sulle patologie da Pneumococco).
11. Romano G, Poli A, Tardivo S. Invasive pneumococcal diseases in age group 0-36 months: results from a perspective surveillance program in Northern-eastern Italy. Poster of ISPPD-4 Helsinki 2004.
12. www.simi.iss.it/meningitebatterica.htm.
13. www.simi.iss.it/meningitebatterica.sintesi
14. Foglietto illustrativo “Prevenar”.
15. Perez A, Sala P, Gimenez M, et al. Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona. Eur J Clin Microbiol Infect Dis 2004;23(9):677-81.
16. Sheldon L, Kaplan S, Mason E et al. Decrease of Invasive Pneumococcal Infections in Children Among Hospitals in the United States After the Introduction of the7-Valent Pneumococcal Conjugate Vaccine. Pediatrics 2004; 113:443-9.
17. Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by SP and SA in healthy children. Lancet 2004;363:1871-72.
18. Regev-Yochay G, Dagan R, Raz M, et al. Association between carriage of SP and SA in children. JAMA 2004,292(6):716-20.
19. Lee KC, Finkelstein JA, Miroshnik I, et al. Pediatricians’ self-reported clinical practices and adherence to national immunization guidelines after the introduction of pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med 2004;158(7):695-701.
20. Van Damme P. Recent increase in meningococcal deaths in Scotland prompts call for vigilance. Eurosurveillance Weekly 2004; (8)Issue 44.
21. Cano R. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Eurosurveillance Monthly 2004;9(7-8):5-6.
22. Piano Nazionale Vaccini 1999-2000.
23. Studio ICONA 1996.
24. Studio ICONA 2003.
25. Osservatorio Epidemiologico Regionale, Bollettino Malattie Infettive, marzo 2004; pag. 6-7.
26. Calendario FIMP 2004.
27. Di Mario S, Magrini N, Amarri S, et al. Vaccinazione antinfluenzale di massa in età pediatrica: quali evidenze abbiamo? Medico e Bambino 2004;23(1):38-46.
28. Nicholson KG, Wood JM, Zambon M. Influenza Lancet 2003;362:1733-45.
29. Christy C, Aligne CA, Auinger P, Pulcino T, Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbation. Arch Dis Child 2004;89:734-5 .
30. Bueving HJ, Bernsen RM, de Jongste JC, et al. Influenza vaccination in children with asthma: randomized double-blind placebocontrolled trial. Am J Resp Crit Care Med 2004;169:488-93.
31. Brisson M. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000;125:651- 69.
32. Salmaso S. Valutazione del potenziale impatto in Italia di programmi estesi di vaccinazione antivaricella secondo un modello matematico. Epidemiologia e Prevenzione 2003; 3:154-160.
33. Ciofi M. La prevenzione della varicella in Italia: strategie di vaccinazione. Istituto Superiore di Sanità. http://www.epicentro.iss.it/focus/ varicella/varicella_ciofi.htm.
34. Brisson M. Exposure to varicella boosts immunity to herpes-zoster: implication for mass vaccination against chickenpox. Vaccine 2002;20:2500-7.
35. Thomas SL. Contacts with varicella or with children and protection against herpes zoster in adults: a case control study. Lancet 2002; 360:678-682.
36. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 2002; 347(24):1909-15.
37. Wise RP. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284(10): 1271-79.
2. Grandori L, D’Andrea N. Un calendario vaccinale nuovo e diverso? Quaderni acp 2003; Vol X n°3:6-7.
3. OMS. Pneumococcal vaccines. Weekly Epidemiological Record 2003;78(14):110-19.
4. Tite L. Drug company pushes for all children under 2 to be vaccinated against pneumonia. BMJ 2003;327:1249.
5. Melegaro A, Edmunds WJ. Cost effectiveness analysis of PNC conjugate vaccination in England and Wales. Vaccine 2004;22:4203-14.
6. CDC. Preventing pneumococcal disease among infants and young children. MMWR 2000;49:RR-9.
7. Whitney CG. Decline in invasive pneumococcal disease after the introduction of portein- polysaccaride conjugate vaccine. N Engl J Med 2003;348:1737-46.
8. Pneumococco: perché vaccinare mio figlio? Pacini editore, pag. 8-9.
9. Tarallo L and the Italian Pneumonet Group (Società Italiana Pediatria and Associazione Italiana Studio Antimicrobici e Resistenze). Active surveillance of S. pneumoniae bacteremia in Italian children. Poster al Convegno Nazionale, Roma, 8 Sett. 2003.
10. Castiglia P, Gallisai D, Sotgiu G. Epidemiology of invasive pneumococcal infections in Sardinian children; Poster of ISPPD-4 Helsinki 2004 (4° simposio internazionale sulle patologie da Pneumococco).
11. Romano G, Poli A, Tardivo S. Invasive pneumococcal diseases in age group 0-36 months: results from a perspective surveillance program in Northern-eastern Italy. Poster of ISPPD-4 Helsinki 2004.
12. www.simi.iss.it/meningitebatterica.htm
13. www.simi.iss.it/meningitebatterica.sintesi
14. Foglietto illustrativo “Prevenar”.
15. Perez A, Sala P, Gimenez M, et al. Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona. Eur J Clin Microbiol Infect Dis 2004;23(9):677-81.
16. Sheldon L, Kaplan S, Mason E et al. Decrease of Invasive Pneumococcal Infections in Children Among Hospitals in the United States After the Introduction of the7-Valent Pneumococcal Conjugate Vaccine. Pediatrics 2004; 113:443-9.
17. Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by SP and SA in healthy children. Lancet 2004;363:1871-72.
18. Regev-Yochay G, Dagan R, Raz M, et al. Association between carriage of SP and SA in children. JAMA 2004,292(6):716-20.
19. Lee KC, Finkelstein JA, Miroshnik I, et al. Pediatricians’ self-reported clinical practices and adherence to national immunization guidelines after the introduction of pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med 2004;158(7):695-701.
20. Van Damme P. Recent increase in meningococcal deaths in Scotland prompts call for vigilance. Eurosurveillance Weekly 2004; (8)Issue 44.
21. Cano R. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Eurosurveillance Monthly 2004;9(7-8):5-6.
22. Piano Nazionale Vaccini 1999-2000.
23. Studio ICONA 1996.
24. Studio ICONA 2003.
25. Osservatorio Epidemiologico Regionale, Bollettino Malattie Infettive, marzo 2004; pag. 6-7.
26. Calendario FIMP 2004.
27. Di Mario S, Magrini N, Amarri S, et al. Vaccinazione antinfluenzale di massa in età pediatrica: quali evidenze abbiamo? Medico e Bambino 2004;23(1):38-46.
28. Nicholson KG, Wood JM, Zambon M. Influenza Lancet 2003;362:1733-45.
29. Christy C, Aligne CA, Auinger P, Pulcino T, Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbation. Arch Dis Child 2004;89:734-5 .
30. Bueving HJ, Bernsen RM, de Jongste JC, et al. Influenza vaccination in children with asthma: randomized double-blind placebocontrolled trial. Am J Resp Crit Care Med 2004;169:488-93.
31. Brisson M. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000;125:651- 69.
32. Salmaso S. Valutazione del potenziale impatto in Italia di programmi estesi di vaccinazione antivaricella secondo un modello matematico. Epidemiologia e Prevenzione 2003; 3:154-160.
33. Ciofi M. La prevenzione della varicella in Italia: strategie di vaccinazione. Istituto Superiore di Sanità. http://www.epicentro.iss.it/focus/ varicella/varicella_ciofi.htm.
34. Brisson M. Exposure to varicella boosts immunity to herpes-zoster: implication for mass vaccination against chickenpox. Vaccine 2002;20:2500-7.
35. Thomas SL. Contacts with varicella or with children and protection against herpes zoster in adults: a case control study. Lancet 2002; 360:678-682.
36. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 2002; 347(24):1909-15.
37. Wise RP. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284(10): 1271-79.